Literature DB >> 25962362

Paraoxonase (PON1) polymorphisms Q192R and L55M are not associated with human longevity: A meta-analysis.

Gan-Zhong Wei1, Mei-Yan Zhu1, Fang Wang1, Yue-Guang Zhao1, Shan-Shan Li1, Tong-Yang Liu1, Ying Luo1, Wen-Ru Tang2.   

Abstract

BACKGROUND: Genetic mutations in the paraoxonase 1 (PON1) encoding gene have been considered to affect mortality and of these the functional promoter region polymorphisms Q192R and L55M are among the most widely studied.
OBJECTIVE: The aim of this study was to determine whether the Q192R and L55M polymorphisms of PON1 can increase susceptibility to longevity. A meta-analysis was performed to obtain a comprehensive estimation of the association between Q192R and L55M and longevity in long-lived individuals (LLIs) aged 80 years or more.
MATERIAL AND METHODS: A search was carried out in the PubMed database (from January 2001 to May 2014) to obtain data on the role of PON1 polymorphisms in longevity and a pooled odds ratio (OR) with a 95% confidence interval (CI) was used to assess the associations.
RESULTS: The meta-analysis was based on 9 studies of PON1 Q192R and 5 studies of PON1 L55M that covered a total of 5086 LLIs and 4494 controls. Overall, significantly increased risks were not observed for either Q192R or L55M. The results of the statistical calculations were as follows: R vs. Q (additive model): OR = 1.080, 95% CI = 0.989-1.179, p = 0.088 and RR + RQ vs. QQ (dominant model): OR = 1.099, 95% CI = 0.975-1.240, p = 0.124; M vs. L (additive model): OR = 0.946, 95% CI = 0.862-1.039, p = 0.245 and MM + ML vs. LL (dominant model): OR = 0.951, 95% CI = 0.836-1.081, p = 0.442 for Q192R and L55M, respectively. The results did not change with an age cut-off among the LLIs of ≥ 93 years.
CONCLUSION: No evidence that the Q192R and L55M polymorphisms of PON1 impacted on the probability of reaching extreme ages was found although this cannot be completely ruled out; however, the possibility of population-specific effects due to the influence of and interaction between different genes or environmental factors could not be ruled out.

Entities:  

Keywords:  Aged, 80 and over; Aging genetics; Alleles; Genotype; Humans

Mesh:

Substances:

Year:  2015        PMID: 25962362     DOI: 10.1007/s00391-015-0892-1

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  32 in total

1.  SPE-HPLC purification of endocrine-disrupting compounds from human serum for assessment of xenoestrogenic activity.

Authors:  Philip Sebastian Hjelmborg; Mandana Ghisari; Eva Cecilie Bonefeld-Jorgensen
Journal:  Anal Bioanal Chem       Date:  2006-06-03       Impact factor: 4.142

Review 2.  The genetics of human longevity.

Authors:  Miriam Capri; Stefano Salvioli; Federica Sevini; Silvana Valensin; Laura Celani; Daniela Monti; Graham Pawelec; Giovanna De Benedictis; Efstathios S Gonos; Claudio Franceschi
Journal:  Ann N Y Acad Sci       Date:  2006-05       Impact factor: 5.691

3.  The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4.

Authors:  P J Talmud; J W Stephens; E Hawe; S Demissie; L A Cupples; S J Hurel; S E Humphries; J M Ordovas
Journal:  Ann Hum Genet       Date:  2005-11       Impact factor: 1.670

4.  Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans.

Authors:  Marion Dietrich; Youqing Hu; Gladys Block; Estibaliz Olano; Lester Packer; Jason D Morrow; Mark Hudes; Gulbahar Abdukeyum; Gerald Rimbach; Anne M Minihane
Journal:  Lipids       Date:  2005-04       Impact factor: 1.880

5.  Vitamin C and E intake is associated with increased paraoxonase activity.

Authors:  Gail P Jarvik; Nancey Trevanian Tsai; Laura A McKinstry; Roohi Wani; Victoria H Brophy; Rebecca J Richter; Gerard D Schellenberg; Patrick J Heagerty; Thomas S Hatsukami; Clement E Furlong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-08-01       Impact factor: 8.311

6.  Quercetin up-regulates paraoxonase 1 gene expression with concomitant protection against LDL oxidation.

Authors:  Maokai Gong; Mamatha Garige; Ravi Varatharajalu; Philippe Marmillot; Chandra Gottipatti; Leslie Castillo Leckey; Raj M Lakshman
Journal:  Biochem Biophys Res Commun       Date:  2009-01-12       Impact factor: 3.575

7.  Paraoxonase 1 polymorphisms and survival.

Authors:  L Christiansen; L Bathum; H Frederiksen; K Christensen
Journal:  Eur J Hum Genet       Date:  2004-10       Impact factor: 4.246

8.  Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans.

Authors:  Manjunath N Rao; Philippe Marmillot; Maoka Gong; David A Palmer; Leonard B Seeff; Doris B Strader; M Raj Lakshman
Journal:  Metabolism       Date:  2003-10       Impact factor: 8.694

9.  Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2.

Authors:  Sara Deakin; Ilia Leviev; Sophie Guernier; Richard W James
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-09-18       Impact factor: 8.311

10.  Paraoxonase 1 response to a high-fat diet: gender differences in the factors involved.

Authors:  Elena Thomàs-Moyà; Magdalena Gianotti; Ana M Proenza; Isabel Lladó
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

View more
  1 in total

Review 1.  Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance.

Authors:  Nelusha Shunmoogam; Poobalan Naidoo; Robert Chilton
Journal:  Vasc Health Risk Manag       Date:  2018-06-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.